Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women.

PubWeight™: 1.21‹?› | Rank: Top 10%

🔗 View Article (PMC 3078690)

Published in Cancer Epidemiol Biomarkers Prev on December 20, 2010

Authors

Rachel L Winer1, James P Hughes, Qinghua Feng, Long Fu Xi, Stephen Cherne, Sandra O'Reilly, Nancy B Kiviat, Laura A Koutsky

Author Affiliations

1: Department of Epidemiology, University of Washington, 325 9th Avenue, Seattle, WA 98104, USA. rlw@u.washington.edu

Articles citing this

Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65

Evidence and impact of human papillomavirus latency. Open Virol J (2012) 1.20

Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ (2012) 1.19

Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3. Int J Cancer (2012) 1.03

Association of Chlamydia trachomatis infection with redetection of human papillomavirus after apparent clearance. J Infect Dis (2013) 0.91

High frequency of human papillomavirus detection in the vagina before first vaginal intercourse among females enrolled in a longitudinal cohort study. J Infect Dis (2012) 0.90

Viral load and short-term natural history of type-specific oncogenic human papillomavirus infections in a high-risk cohort of midadult women. Int J Cancer (2013) 0.89

Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16. J Infect Dis (2013) 0.88

Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women. J Med Virol (2013) 0.84

Characterizing the temporal dynamics of human papillomavirus DNA detectability using short-interval sampling. Cancer Epidemiol Biomarkers Prev (2013) 0.84

Short-term natural history of high-risk human papillomavirus infection in mid-adult women sampled monthly. Int J Cancer (2015) 0.83

Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype. Virology (2014) 0.80

DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women. Sex Transm Infect (2013) 0.79

Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1. J Biomed Sci (2013) 0.77

HPV clearance in postpartum period of HIV-positive and negative women: a prospective follow-up study. BMC Infect Dis (2013) 0.77

The Association Between Cervical Human Papillomavirus Infection and Subsequent HIV Acquisition in Tanzanian and Ugandan Women: A Nested Case-Control Study. J Infect Dis (2016) 0.76

Location and Density of Immune Cells in Precursor Lesions and Cervical Cancer. Cancer Microenviron (2012) 0.76

Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination. Curr Epidemiol Rep (2015) 0.75

Clinical Utility of Molecular Biomarkers in Cervical Squamous Intraepithelial Lesions in a Young Adult Population. J Low Genit Tract Dis (2016) 0.75

High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes. Sci Rep (2017) 0.75

Screening adolescents and young women. Obstet Gynecol Clin North Am (2013) 0.75

Articles cited by this

Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35

Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61

Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31

Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15

Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA (1994) 2.71

Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51

Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51

Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res (2006) 1.82

A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis (2007) 1.62

Obtaining sensitive data through the Web: an example of design and methods. Epidemiology (2002) 1.61

The geographical and temporal evolution of sexually transmitted disease epidemics. Sex Transm Infect (2002) 1.46

Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer (2009) 1.37

A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis (2004) 1.36

Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol (2008) 1.35

Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis (2009) 1.18

Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis (2008) 1.09

Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol (2009) 1.06

Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis (1996) 1.01

Articles by these authors

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67

Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials (2006) 7.50

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35

Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09

Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20

Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med (2005) 3.96

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55

Human L1 element target-primed reverse transcription in vitro. EMBO J (2002) 3.54

Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ (2010) 3.41

Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19

Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet (2007) 3.10

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98

HIV serosorting in men who have sex with men: is it safe? J Acquir Immune Defic Syndr (2008) 2.91

Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol (2008) 2.80

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78

HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru. J Acquir Immune Defic Syndr (2007) 2.71

Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59

Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51

Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42

Tyrosol is a quorum-sensing molecule in Candida albicans. Proc Natl Acad Sci U S A (2004) 2.39

Genital human papillomavirus infection in men. Lancet Infect Dis (2006) 2.39

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA (2002) 2.37

Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36

Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis (2009) 2.26

Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis (2006) 2.21

Male circumcision, religion, and infectious diseases: an ecologic analysis of 118 developing countries. BMC Infect Dis (2006) 2.10

Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09

Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst (2005) 2.08

Prevalences of sexually transmitted infections in young adults and female sex workers in Peru: a national population-based survey. Lancet Infect Dis (2012) 2.03

Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01

Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis (2002) 1.99

Development and performance of a microwell-plate-based polymerase chain reaction assay for Mycoplasma genitalium. Sex Transm Dis (2003) 1.99

Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol (2008) 1.96

Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol (2003) 1.91

Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis (2003) 1.91

Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis (2002) 1.87

Handheld computers for self-administered sensitive data collection: a comparative study in Peru. BMC Med Inform Decis Mak (2008) 1.82

Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet (2012) 1.80

Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78

Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis (2012) 1.78

Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health (2007) 1.78

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74

Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69

DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2008) 1.68

Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis (2012) 1.67

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66

Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst (2009) 1.65

Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr (2007) 1.63

Obtaining sensitive data through the Web: an example of design and methods. Epidemiology (2002) 1.61

Correlates of national HIV seroprevalence: an ecologic analysis of 122 developing countries. J Acquir Immune Defic Syndr (2004) 1.59

HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med (2013) 1.59

Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol (2003) 1.58

Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res (2005) 1.58

An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (2013) 1.55

HIV testing frequency among men who have sex with men attending sexually transmitted disease clinics: implications for HIV prevention and surveillance. J Acquir Immune Defic Syndr (2009) 1.55

Clandestine induced abortion: prevalence, incidence and risk factors among women in a Latin American country. CMAJ (2009) 1.55

Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Hum Resour Health (2007) 1.51

Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis (2004) 1.50

Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clin Chem (2004) 1.50

Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48